magnesium oxide (Tecnimede)

Metabol-MG is a pharmaceutical formulation of magnesium oxide (heavy) developed by the Portuguese company Tecnimede. It is primarily investigated as an adjunctive therapy for patients with type 2 diabetes mellitus who also suffer from hypomagnesemia. Magnesium is an essential mineral that serves as a cofactor for over 300 enzymatic reactions, including those involved in glucose metabolism and insulin signaling. Specifically, magnesium is required for the autophosphorylation of the insulin receptor and the activity of tyrosine kinase, thereby enhancing insulin sensitivity. Hypomagnesemia is common in diabetic patients due to increased urinary excretion and is linked to insulin resistance and poor glycemic control. Metabol-MG aims to correct this deficiency to improve metabolic outcomes. It has been evaluated in Phase 2 clinical trials in Portugal for its efficacy in improving glycemic control when added to standard oral antidiabetic regimens.

Brand names

Metabol-MG

Other names

magnesium oxideheavy magnesium oxideMgO